Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based clinical-stage biotechnology company, announced on Thursday that it has added Sanjay Juneja, MD to its Cancer Business Advisory Board.
Dr Juneja, a board-certified haematologist and medical oncologist, is presently practicing in Baton Rouge, Louisiana. He has served on the White House Leaders in Social Media roundtable and has been featured by The Washington Post, CNBC, PBS, and WebMD, among many others. He serves as an editorial board member for the peer-reviewed research journal AI in Precision Oncology, and as a contributor to Entrepreneur Magazine.
Anixa chairman and CEO Dr Amit Kumar, said, 'Dr Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most importantly, his public voice empowers cancer patients with knowledge, support, and hope. We anticipate that Sanjay's rapidly growing national profile will aid in educating the cancer community about the novelty of our vaccines and therapeutics. His broad reach will be beneficial to Anixa as we advance our programs, including enrolment and site recruitment for our current and upcoming clinical trials.'
Sanofi and Orano partner to advance radioligand therapies
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies